AllDocs -> cancers

F L A X — Y O U R M I R A C L E M E D I C I N E Men’ s Health U niversity of California at Los Angeles scientists reported January 14, 2003 that 11 days of daily exercise and a low-fat, high- fiber diet can induce prostate cancer cells to die. This is important news for men with prostate cancer or for those men who desire to remain free from prostate cancer . In addition, the new research demonstrates that, once again, our Healthy Living recommendation to men to include Barlean’s Forti-Flax milled flaxseed in their daily diet is right on target. Combination of Exercise & Fiber Kills Cancer Cells The research, published in the jour- nal Cancer Causes and Control , is the first to show that diet and exercise can kill prostate cancer cells. “You can make changes in a short ...

C O M P L E M E N T A R Y C A N C E R T H E R A P E U T I C S Natural Health Haelan 951 & Prostate Cancer —Experience Powerful Benefits of Fermented Soy “T he small soybean (about 1 / 4 inch) has been causing quite a stir in scientific circles because of its potent phytochemicals and nutritional attributes,” notes Patti Milligan, M.S., R.D., a registered dieti- tian with nearly 20 years experience in nutritional science and preventive med- icine. “The common soybean first became a food staple in ancient China approximately 5,000 years ago. By the year 300 B.C., cultivation of soybeans and their use as food spread to Korea, Japan, Southeast Asia, and, finally, about 1,000 years later, to Europe.” Milligan is especially excited about the benefits of soy for protecting against ...

PCNG PROSTATE CANCER NETWORKING GROUP of Greater Cincinnati Founder: Bob Kanter - Convener: Robert Young - Conveners Emeriti: Adrian Boie, Lou Stadler - Newsletter: Kees DeJong & Fran Stanton- Treasurer: Jerry Smith, 1621 Raglan Av., Cincinnati OH 45230 – Please, make checks payable to the Wellness Community 779-0144 Adrian Boie: 1989, PSA 13, GS 9; RP, EBRT, IHT 751-6888 Kees DeJong: 1996, PSA 24, GS 9; IHT 221-6736 John Hoffmann: 1997, PSA 5, GS 6, RP, EBRT TELEPHONE CONTACTS: 528-2769 Gordon Huntley: 1999, PSA 4, GS 9, RP and Orchiectomy 733-5745 Bill Riggs: 1995, PSA 33, GS 6, RP, EBRT, HT 761-9645 Lou Stadler: 1987, PSA NA, GS 7; EBRT, HT 542-4908 Fran Stanton: 1999, PSA 157, GS 8; HT, EBRT+Brachy 321-1693 Robert Young: 1999, PSA >1,000, GS 7; HT 19xx: year of ...

P REVIEWS IN U ROLOGY Previews in Urology highlights topics of interest to urologists through the points of view of the companies that sponsor publication of this journal; the material has not been reviewed by the Medical and Contributing Editors. Progress in Prostate Cancer : Abbott Oncology Scientists at Abbott Laboratories are working hard every day to uncover new options in cancer therapy. Abbott Oncology is committed to the discovery and development of innovative treatments to help physicians improve the lives of their cancer patients. Abbott’s commitment, in addition to targeted anti- cancer pharmaceuticals, includes a broad range of health care products, from supportive care products for pain management to diagnostics tests for the detection of cancer , to products that address the nutritional needs of cancer patients. Committed ...

10974 10901 10931 10977 10952 10984 10970 10980 10965 10954 10956 10923 10927 10920 10986 10993 10962 10913 10994 10989 10960 10976 10983 10964 10968 Comparison of individual zip codes with expected incidence more than 100% above expected 50% to 100% above expected 15% to 49% above expected within 15% of expected 15% to 50% below expected more than 50% below expected very sparse data Areas of elevated incidence not likely due to chance more than 100% above expected 50% to 100% above expected Prostate Cancer Incidence by ZIP Code Adjusted for Age and Race Rockland County 1994-1998

13843 13809 13808 13849 13849 13411 13335 13485 13810 13825 13796 13491 13348 13315 13820 13861 13439 13337 13326 13439 12116 13834 13807 12197 12155 13468 13320 13317 13459 Comparison of individual zip codes with expected incidence more than 100% above expected 50% to 100% above expected 15% to 49% above expected within 15% of expected 15% to 50% below expected more than 50% below expected very sparse data Areas of elevated incidence not likely due to chance more than 100% above expected 50% to 100% above expected Prostate Cancer Incidence by ZIP Code Adjusted for Age and Race Otsego County 1994-1998

14125 14105 14103 14098 14058 14411 14477 14571 14416 14420 14470 14476 Comparison of individual zip codes with expected incidence more than 100% above expected 50% to 100% above expected 15% to 49% above expected within 15% of expected 15% to 50% below expected more than 50% below expected very sparse data Areas of elevated incidence not likely due to chance more than 100% above expected 50% to 100% above expected Prostate Cancer Incidence by ZIP Code Adjusted for Age and Race Orleans County 1994-1998

14589 14513 14502 14522 14568 14519 14505 14555 13146 14433 14489 14551 14516 14590 13143 Comparison of individual zip codes with expected incidence more than 100% above expected 50% to 100% above expected 15% to 49% above expected within 15% of expected 15% to 50% below expected more than 50% below expected very sparse data Areas of elevated incidence not likely due to chance more than 100% above expected 50% to 100% above expected Prostate Cancer Incidence by ZIP Code Adjusted for Age and Race Wayne County 1994-1998

10701 10550 10704 10705 10710 10703 10546 10594 10532 10570 10510 10562 10520 10548 10511 10566 10547 10588 10598 10502 10522 10706 10523 10530 10533 10607 10591 10595 10553 10552 10801 10805 10709 10804 10538 10583 10543 10580 10528 10803 10708 10604 10603 10606 10601 10573 10504 10577 10605 10514 10501 10505 10541 10578 10526 10506 10507 10536 10549 10589 10518 10576 10590 10597 10560 Comparison of individual zip codes with expected incidence more than 100% above expected 50% to 100% above expected 15% to 49% above expected within 15% of expected 15% to 50% below expected more than 50% below expected very sparse data ...

Current Pharmaceutical Design, 2003 , 9, 455-466 455 1381-6128/03 $41.00+.00 © 2003 Bentham Science Publishers Ltd. Drug-Targeting Strategies for Prostate Cancer Gil Ast * Department of Human Genetics and Molecular Medicine, Sackler School of Medicine,Tel Aviv University, Israel Abstract: Prostate cancer is the most frequently diagnosed cancer in North American men and accounts for 10% of cancer -related deaths in men. Despite advances in early detection and aggressive treatment of early disease, the overall mortality rate has not appear to have fallen, indicating that the current therapies are not beneficial for life expectancy and new strategies are required. Prostate cancer is a dynamic evolving process that develops in distinct steps, with each step liable to additional genetic hits that change the cancer cell phenotype and alter the ...

BOARD DECLARES SEPTEMBER 2001 AS PROSTATE CANCER AWARENESS MONTH September 24, 2001 For Immediate Release Christiansburg, Virginia – At its September 10 meeting, the Montgomery County Board of Supervisors unanimously proclaimed September as Prostate Cancer Awareness Month in Montgomery County. The Board’s resolution “urge(d) all men in Montgomery County to become aware of their own risks of prostate cancer , talk to their health care providers about prostate cancer , get screened for the disease whenever appropriate, and encourage all residents to become involved in the war on prostate cancer through this County’s education and advocacy initiatives.” The Board recognized further that : • In 2001 approximately 198,000 men in the United States will learn they have prostate cancer , and across the nation, prostate ...

PROJECT 1 – MOLECULAR PREDICTORS OF PROSTATE CANCER PROGRESSION & MORTALITY Prostate cancer (CaP) is the most frequently diagnosed solid tumor and the second leading cause of cancer deaths among U.S. men. Despite the substantial morbidity and mortality associated with CaP, limited attention has been focused on elucidation of factors that predict clinical disease progression or mortality. Environmental and genetic factors may play a role in the development of aggressive, life-threatening CaP. We hypothesize that variant alleles in genes involved in the androgen/growth factor/antioxidant pathways confer a higher risk for disease progression and mortality. Specifically, we propose to genotype a population-based cohort of CaP patients to address the following hypotheses: 1) Heterozygotes and homozygotes for the valine allele (V89L) in the SRD5A2 gene have an increased risk of prostate cancer progression ...

Adult Neuro-Oncology Branch Clinical Trials National Cancer Institute in Bethesda, Maryland CONTACT INFORMATION: Call the Neuro-Oncology Patient Referral Line at 301-402-6298 Study Title and Basic Eligibility Treatment Plan Any primary CNS tumor NCI-01-C-0070 Evaluation of the natural history of patients with CNS tumors • Patients must have CNS tumor NCI-02-C-0140 A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas • Any patient with radiographic suggestion of a primary glial neoplasm or known glial neoplasm who will undergo a medically indicated (diagnostic and/or therapeutic) tumor resection or biopsy • Non-pharmacologic treatment protocol • Patients will be followed by consult • Diagnostic testing may be performed • Patients will have opportunity to be screened for ...

] 164 Tel. 972 8 934 Fax. 972 8 934 E-mail: state and during changing conditions. It has the capability to provide image contrast based on several independent nuclear magnetic properties as well as on metabolic and physiologic characteristics. It can also image molecules tagged with magnetically sensitive probes and thereby enhance molecular targeted imaging. The imaging technology developed in our laboratory in recent years reached the state of clinical testing. New parametric MRI methods, including the 3TP (Three Time Point) method for the diagnosis of prostate cancer and of breast cancer are being evaluated in Israel (Tel Aviv Sourasky Medical Center) and USA (University of Wisconsin, Illinois Masonic Medical Center, Hospital of Boca Raton). An example of parametric MRI of the prostate is shown in Fig. 1. Our current research activities ...

November/December 2001, Vol. 8, No.6 496 Cancer Control Radical Prostatectomy in the Management of Clinically Localized Prostate Cancer Raviender Bukkapatnam, MD, and Julio M. Pow-Sang, MD Background: Several management options are available when prostate cancer is diagnosed at an early stage. However, the optimal treatment for localized prostate cancer is unknown, and reports in the literature are controversial regarding the best treatment modality for this early presentation. Methods: The authors review improvements in surgical technique that have decreased complications, and they address long-term outcomes of surgery related to cancer control. Results: Improvements in surgical techniques allow for decreased intraoperative complications. The incidence of long-term complications such as incontinence and impotency is also reduced. The 5- and 10-year progres- ...

Imaging Tool Helps Locate Sites of Early Recurrent Prostate Cancer DURHAM, N.C. -- A new multi-institutional study led by investigators at Duke University Medical Center indicates that a diagnostic scan may help localize recurrent prostate disease in men who have had surgical removal of the prostate and show early signs of recurrence. This diagnostic scan, called capromab pendetide immunoscintigraphy, trade name ProstaScint®, is a monoclonal antibody scan that can detect recurrent disease if it is localized to the area of prior prostate surgery or has spread to other parts of the body. This knowledge can help doctors better decide which type of treatment would work best for each patient with recurrent prostate cancer . The study appears in the Feb. 15, 2002 issue of the journal Cancer . Surgical removal of the prostate and surrounding lymph nodes called radical prostatectomy is an effective ...

Diet May Help Prevent Prostate Cancer Suggested lead: A diet high in fiber and low in fat could help prevent prostate cancer . Tom Britt has more. Cut 1SOQ:60 . (Preview this in a WAV file in 16-bit mono.) Researchers at Duke University Medical Center recently put a group of prostate cancer patients awaiting surgery on a diet that included plenty of low fat foods and flaxseed. They found that the men had significant decreases in testosterone and cholesterol, and many of them showed a decrease in their PSA -- an indicator of the presence of prostate cancer . Research professor and study director Wendy Demark says the diet also appears to have slowed the growth of the cancer . "Their prostate cancer cells were splitting/dividing at a much lesser rate and their cancer cells were also destroying themselves a lot faster." Demark says it is still far too preliminary to advise all men ...

Morris Foundation Commits $2 Million for Prostate Cancer Research at Duke The Edwin A. Morris Charitable Foundation of Durham and Greensboro has made its largest single gift ever, a $1 million commitment to the Duke Comprehensive Cancer Center. The gift will combine with an additional $1 million from the E. A. Morris Endowment to establish the Morris Center for Urologic Research, Duke University President Nannerl O. Keohane announced Monday. Greensboro apparel manufacturing executive Edwin A. Morris, who died in 1998, established the E.A Morris Endowment at the university in 1986 to support Duke University Medical Center's cancer research and facilities. "For more than two decades, the generosity of Edwin Morris has helped make Duke a leader in cancer care and research," Keohane said. "We are most grateful for this latest gift, which will help place Duke at the forefront of efforts to combat prostate ...

Last revised: 3/2/04 UM Comprehensive Cancer Center Patient Education Document #0034 May03 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm 1 University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Prostate Cancer The purpose of this information guide is to help patients newly diagnosed with prostate cancer and their families to find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center (PERC) at the University of Michigan Comprehensive Cancer Center in room B1-361. Reference Available at the Patient Education Resource Center on Level B-1 room 261 ...

H:\EVERYONE\SYSTEMIC\Chemo\Protocol\GU\GUEMCYT.doc GUEMCYT Interim Version Last revised 1 Sep 1999 Page 1 of 3 BCCA Protocol Summary for Androgen-Independent Prostate Cancer using Estramustine Phosphate (Interim Version) Protocol Code GUEMCYT Protocol Group Genitourinary Contact Physician Dr. Chris Coppin GU Systemic Therapy Contacts CCSI Drs Susan Ellard, Judy Sutherland FVCC Dr Chris Coppin VCC Drs Nevin Murray, Cicely Bryce, Kim Chi VICC Drs Heidi Martins, Catherine Fitzgerald ELIGIBILITY/TESTS: N.B. Estramustine phosphate is a BCCA Class II agent and is only provided as a free drug benefit to eligible patients. This drug is not approved for use in combination with chemotherapy. Biopsy proven prostate cancer Metastatic disease or local progression after radiation Progressive evaluable disease despite ...

The Prostate Cancer Charity produces a range of leaflets and factsheets about prostate cancer , which we will send free of charge to individuals in the UK. We also provide a Confidential Helpline 0845 300 8383 staffed by experienced nurses. It is open from 10am to 4pm Monday to Friday. The nurses will answer questions from anyone concerned about prostate cancer . Calls may be monitored for training and quality purposes. We also welcome letters and email enquiries. Write to the Information and Support Service at The Prostate Cancer Charity. Prostate Cancer - The Works May 2001 The Prostate Cancer Charity, 3 Angel Walk London W6 9HX Tel: el: 020 8222 7622 Fax: ax: 020 8222 7639 Confidential Helpline: 0845 300 8383 Email: Email: info@ prostate - cancer .org.uk Orders/requests for information, ...

Web Immagini Gruppi Directory News Novità! Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:hSGTx9_pwwMJ:www.dhs.sa.gov.au/pehs/cancer-report-01/pp-prostate.pdf allintitle: prostate cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: - Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. - Provare con un numero minore di parole chiave. ...

TREATMENT OF ORGAN CONFINED PROSTATE CANCER WITH THIRD GENERATION CRYOSURGERY: PRELIMINARY MULTICENTER EXPERIENCE KEN-RYU HAN,* JEFF K. COHEN,* RALPH J. MILLER,* ALLAN J. PANTUCK,* DANIELO G. FREITAS, CARLOS A. CUEVAS, HYUNG L. KIM,* JAMES LUGG,† STACY J. CHILDS,† BARRY SHUMAN,* MAURY A. JAYSON,* NEAL D. SHORE,* YAN MOORE,* AMNON ZISMAN,* JOE Y. LEE,* ROLAND UGARTE,‡ LANCE A. MYNDERSE,* TORRENCE M. WILSON,* SUSAN D. SWEAT,* HORST ZINCKE* AND ARIE S. BELLDEGRUN* , § From the Division of Urologic Oncology (ASB, K-RH, DGF, HLK), Department of Urology (AJP), University of California Los Angeles, Los Angeles, California, Division of Urology, Allegheny General Hospital (JKC) and Allegheny Prostate Center (RJM), Pittsburgh, Pennsylvania, Boston Medical Center (CAC), Boston, Massachusetts, University of Colorado Health Sciences (JL, SJC), Cheyenne, Wyoming, Albany Memorial ...

The Drive Against Prostate Cancer managed by the National Prostate Cancer Coalition 1156 15th Street, NW, Washington, DC 20005 888.245.9455 (toll-free phone) G 202.463.9456 (fax) www.psa-to-go.org Sponsors Thor Industries G Dianon Systems Inc. G Bayer Diagnostics G Airborne Express Cancer Research Institute G Dattoli Brachytherapy and Cancer Research Institute Drive Against Prostate Cancer Request for Vehicle Application Thank you for your interest in DAPC. Organizations like yours help us achieve our goals to spread awareness about Prostate Cancer through medical screenings and proper education. Please fill out this form and you will be contacted within two weeks. Name of Organization Contact Name Contact Phone Contact Fax Contact Email Contact Address City State Zip ...

UCLA PROSTATE CANCER INDEX Short Form (UCLA-PCI-SF), including the RAND 12-Item Health Survey v2 (SF-12 v2) HEALTH-RELATED QUALITY OF LIFE SCORING INSTRUCTIONS © 1999 Mark S. Litwin, MD, MPH mlitwin@ucla.edu Page 2 Scoring Summary The UCLA Prostate Cancer Index was developed by researchers at UCLA and RAND to measure health-related quality of life (HRQOL) in patients treated for prostate cancer . It addresses general HRQOL and organ-targeted HRQOL. The instrument has been validated psychometrically in this population. Reliability and validity statistics for the instrument are included in reference 7. The Index contains three parts. This document explains the scoring rules for each of these parts. The components of the Index are: 1. RAND 12-Item Health Survey v2 (SF-12 v2) Items 1-7 ...

PROSTATE CANCER INFORMATION INFORMATION SITES Adelaide Lions Australia Prostate Cancer Website (Incorporating Daw Park Repatriation General Hospital’s, Mr Phip Project) www.prostatehealth.org.au Prostate Support Awareness (Adelaide) www.psaadelaide.org Prostate Cancer Support, Onkaparinga Group www.pcsog.org The Cancer Council South Australia www.cancersa.org.au Email: tcc@cancersa.org.au Cancer Connect - Cost local call 131120 ( Prostate Assistance) Prostate Cancer Action Group (SA) Inc. www.pcagsa.org.au Sydney NSW Prostate Cancer Foundation of Australia www. prostate .org.au YANANOW: www.yananow.net Melbourne VIC Andrology Australia www.andrologyaustralia.org WHERE DO WE MEET? Adelaide Group Meeting: Once a month ...

[ CANCER RESEARCH 63, 2228 –2233, May 1, 2003] Androgen-independent Growth of LNCaP Prostate Cancer Cells Is Mediated by Gain-of-Function Mutant p53 1 Nancy J. Nesslinger, Xu-Bao Shi, and Ralph W. deVere White 2 Department of Urology, University of California, Davis, School of Medicine, Sacramento, California 95817 ABSTRACT Mutations of p53 are common in hormone-refractory prostate cancer (CaP), suggesting the possibility that these mutations may be involved in the progression of CaP to androgen-independent (AI) growth. However, at present no direct evidence has been presented linking p53 mutations with AI growth of CaP. We established five stably transfected LNCaP cell lines: four containing gain-of-function (GOF) mutant p53 alleles ( G245S, R248W, R273H, and R273C ) and one containing a non-GOF p53 mutant allele ...

Clark County Health Department 2003 Prostate Cancer Clark County and Washington State, 1994 through 2001 Status: - Clark County's prostate cancer incidence rate has declined since the early 1990's while the statewide rate is showing a slight increase in recent years.(3) -The incidence rate generally increased with age until 70 to 79 years of age. In most age groups the risk of prostate cancer was higher in men statewide compared with Clark County men.(3) - The prostate cancer death rates in both the county and the state remained steady and were close to meeting the Healthy People 2010 target of fewer than 28.7 deaths per 100,000 population.(4,5,6) - The majority of persons diagnosed with prostate cancer were identified in the early stages of the disease indicating the presence of effective screening programs in this county and statewide. ...

Corporate Medical Policy Prostate Cancer Treatment with Brachytherapy File Name: prostate_cancer_treatment_with_brachytherapy Policy Number: RAD5150 Origination: 12/1997 Last Review: 5/2003 Next Review: 5/2005 Description of Procedure or Service Brachytherapy is a type of radiotherapy which uses ionizing radiation whose source is a short distance from the area that is being treated. Brachytherapy of the prostate is used to treat cancer of the prostate gland. It can be delivered in a variety of ways. The most familiar technique of is the use or radioactive seeds that are permanently implanted into the prostate tissue. These seeds contain radioisotopes of relatively low energy, short half lives, low dose rates, and limited range. The seeds are between 4 and 5 millimeters in size. Place- ment of the seeds is guided by transrectal ultrasound. ...

Priority 1 - Strategically assess opportunities in prostate cancer research, espe- cially its translation into new treatments, and increase appropriate investments. Implement sound accountability mechanisms; include knowledgeable consumers. NIH/NCI must submit a comprehensive professional judgment budget to Congress for its FY04-FY08 prostate cancer investment strategy. This portfolio of opportunities should be prioritized and built upon new advances in prostate cancer molecular biology, genomics, epidemiology and burden of disease, prevention, early detection, diagnosis, treatments, promising clinical trials and survivors' quality of life. Responsible mecha- nisms of oversight must be developed to assure integrity and fulfillment of the strategy. A sound research plan for prostate cancer , like any other business plan, requires both fis- cal and human capital to fulfill ...